PDGF beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 2, 2015, Pages 371-382

  Tudoran, Oana Mihaela ^a   Soritau, Olga ^a   Balacescu, Loredana ^a   Pop, Laura ^b   Meurice, Guillaume ^c   Visan, Simona ^a,d   Lindberg, Staffan ^e   Eniu, Alexandru ^a   Langel, Ulo ^e   Balacescu, Ovidiu ^a   Berindan Neagoe, Ioana ^a,b  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

^e STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Cervical cancer; Microarray; Molecular signalling; PDGFBB

Indexed keywords

PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB;

CARCINOGENESIS; FEMALE; HELA CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; HELA CELLS; HUMANS; PROTO-ONCOGENE PROTEINS C-SIS; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84921691335     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12449     Document Type: Article

References (49)

1. American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta: American Cancer Society; 2011.
2. Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies. Oncol Rep. 2002; 9: 455-60.
3. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438: 967-74.
4. Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell. 2003; 3: 439-43.
5. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111: 1287-95.
6. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004; 18: 338-40.
7. Wei XW, Zhang ZR, Wei YQ. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment. Expert Opin Investig Drugs. 2013; 22: 1181-92.
8. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009; 27: 1069-74.
9. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010; 116: 163-7.
10. Shao M, Rossi S, Chelladurai B, et al. PDGF induced microRNA alterations in cancer cells. Nucleic Acids Res. 2011; 39: 4035-47.
11. Andaloussi SE, Lehto T, Mager I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011; 39: 3972-87.
12. Gulec SA, Woltering EA. A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay. Ann Surg Oncol. 2004; 11: 99-104.
13. Bosco MC, Puppo M, Santangelo C, et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol. 2006; 177: 1941-55.
14. Bosco MC, Pierobon D, Blengio F, et al. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood. 2011; 117: 2625-39.
15. www.ingenuity.com LB, December 2013
16. Crawford Y, Kasman I, Yu L, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009; 15: 21-34.
17. Kuhnert F, Tam BY, Sennino B, et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA. 2008; 105: 10185-90.
18. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl). 2008; 86: 785-9.
19. Guo D, Hu K, Lei Y, et al. Identification and characterization of a novel cytoplasm protein ICF45 that is involved in cell cycle regulation. J Biol Chem. 2004; 279: 53498-505.
20. Krishnan P, Gullen EA, Lam W, et al. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem. 2003; 278: 36726-32.
21. Wang P, Song W, Mok BW, et al. Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein. J Virol. 2009; 83: 7850-61.
22. Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010; 70: 5326-36.
23. McFall A, Ulku A, Lambert QT, et al. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol. 2001; 21: 5488-99.
24. Wang CX, Wadehra M, Fisk BC, et al. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood. 2001; 97: 3890-5.
25. Curtin JF, Cotter TG. JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol Chem. 2004; 279: 17090-100.
26. Foltz G, Yoon JG, Lee H, et al. Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme. Genes Cancer. 2010; 1: 81-90.
27. Sumazin P, Yang X, Chiu HS, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011; 147: 370-81.
28. Gutschalk CM, Herold-Mende CC, Fusenig NE, et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006; 66: 8026-36.
29. Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010; 29: 4980-8.
30. Zhou XL, Qin XR, Zhang XD, et al. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling. Acta Pharmacol Sin. 2010; 31: 202-10.
31. Kremer KN, Kumar A, Hedin KE. G alpha i2 and ZAP-70 mediate RasGRP1 membrane localization and activation of SDF-1-induced T cell functions. J Immunol. 2011; 187: 3177-85.
32. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007; 369: 1742-57.
33. Lee WJ, Chen WK, Wang CJ, et al. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol. 2008; 226: 178-91.
34. Nangia-Makker P, Balan V, Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron. 2008; 1: 43-51.
35. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood. 2003; 101: 1582-90.
36. Lizard G, Chignol MC, Chardonnet Y, et al. Detection of human papillomavirus DNA in CaSki and HeLa cells by fluorescent in situ hybridization. Analysis by flow cytometry and confocal laser scanning microscopy. J Immunol Methods. 1993; 157: 31-8.
37. Ben Khalifa Y, Teissier S, Tan MK, et al. The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63beta upon transformation. PLoS Pathog. 2011; 7: e1002256.
38. Ramirez-Salazar E, Centeno F, Nieto K, et al. HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation. Virol J. 2011; 8: 247.
39. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol. 2000; 157: 1703-11.
40. Spinella F, Garrafa E, Di Castro V, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009; 69: 2669-76.
41. Grieb G, Simons D, Steinberger H, et al. Improved in vitro cultivation of endothelial progenitor cells as basis for dermal substitutes with enhanced angiogenic capabilities. Langenbecks Arch Surg. 2011; 396: 1255-62.
42. Malla RR, Gopinath S, Gondi CS, et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther. 2011; 18: 419-34.
43. Leu SJ, Liu Y, Chen N, et al. Identification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61). J Biol Chem. 2003; 278: 33801-8.
44. Leu SJ, Chen N, Chen CC, et al. Targeted mutagenesis of the angiogenic protein CCN1 (CYR61). Selective inactivation of integrin alpha6beta1-heparan sulfate proteoglycan coreceptor-mediated cellular functions. J Biol Chem. 2004; 279: 44177-87.
45. Athanasopoulos AN, Schneider D, Keiper T, et al. Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing. J Biol Chem. 2007; 282: 26746-53.
46. Lay AJ, Jiang XM, Kisker O, et al. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature. 2000; 408: 869-73.
47. Ohlmann A, Seitz R, Braunger B, et al. Norrin promotes vascular regrowth after oxygen-induced retinal vessel loss and suppresses retinopathy in mice. J Neurosci. 2010; 30: 183-93.
48. Reis M, Czupalla CJ, Ziegler N, et al. Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. J Exp Med. 2012; 209: 1611-27.
49. Ren S, Johnson BG, Kida Y, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA. 2013; 110: 1440-5.